Shionogi logo

Shionogi

SGIOY | OTC
Chart Builder DCF Calculator
$10.01
+$0.14 (+1.47%)
At close: Nov 16, 2026, 3:58 PM ET
$10.04
+$0.03 (+0.30%)
After-hours: Nov 16, 2026, 3:50 PM ET
+1.47%

Rating

Updated: Nov 16, 2026
60.5
Fundamentals Strong
Market Sentiment Bullish
Moat Narrow
Sector Rank #133/1021 (Top 13%)

Key Statistics

Market Data

Market Cap $17.04B
1D Range
9.88 10.09
52W Range
8.35 11.79

Valuation (TTM)

PE 11.12
PB 1.54
EV/EBITDA 9.89

Valuation (NTM)

Forward PE 13.46
Forward PEG 0.62
Price Target $0.00
Loading financial charts...

Profile

Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, ...

Sector Healthcare
Employees 6,223
IPO Date Dec 1, 2015
Fiscal Year April - March

Latest News

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

14 hours ago · zacks.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Not IonQ. Not Rigetti. This Quantum Computing Stock Could Be the Next to Soar.

13 days ago · fool.com

Not IonQ. Not Rigetti. This Quantum Computing Stock Could Be the Next to Soar.
SGIOY vs. UTHR: Which Stock Is the Better Value Option?

18 days ago · zacks.com

SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should Know

1 month ago · zacks.com

Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should Know
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026

2 months ago · businesswire.com

Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

3 months ago · businesswire.com

Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

4 months ago · zacks.com

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth

4 months ago · zacks.com

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth

Earnings

Latest Earnings
Oct 29, 2026
EPS
$0.08
Miss -38.46%
REV
$1.19B
Beat +6.65%
Next Earnings
Jan 29, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.